Skip to main content

Table 4 Characteristics of consenting and not consenting eligible patients

From: The feasibility and acceptability of trial procedures for a pragmatic randomised controlled trial of a structured physical activity intervention for people diagnosed with colorectal cancer: findings from a pilot trial of cardiac rehabilitation versus usual care (no rehabilitation) with an embedded qualitative study

 

Not consenting N (%) total N = 54

Consenting N (%) total N = 41

Age (years)

  N

54

41

 Missing

0

0

 Mean

65.6

66.0

 SD

13.81

11.31

 Median

65.5

67.0

Sex

 Male

39 (72.2)

27 (65.9)

 Female

15 (27.8)

14 (34.1)

Primary tumoura

 Missing

13 (24.1)

9 (22.0)

 T0

2 (3.7)

1 (2.4)

 T1

1 (1.9)

3 (7.3)

 T2

8 (14.8)

12 (29.3)

 T3

20 (37.0)

11 (26.8)

 T4

10 (18.5)

5 (12.2)

Regional lymph nodea

 Missing

19 (35.)

13 (31.7)

 Nx

1 (1.9)

0

 N0

21 (38.9)

22 (53.7)

 N1

13 (24.1)

6 (14.6)

Distant metastasisa

 Missing

48 (88.9)

36 (87.8)

 M0

5 (9.3)

5 (12.2)

 M1

1 (1.9)

0

Colon surgery

  

 Yes

33 (61.1)

25 (61)

 No

21 (38.9)

16 (39)

Rectal surgery

  

 Yes

19 (35.2)

16 (39)

 No

35 (64.8)

25 (61)

Laparoscopic surgery

  

 Missing

1 (1.9)

0 (0)

 No

37 (68.5)

32 (78)

 Yes

16 (29.6)

9 (22)

Open surgery

  

 Missing

1 (1.9)

0

 No

21 (38.9)

18 (43.9)

 Yes

32 (59.3)

23 (56.1)

Temporary stoma

  

 Missing

3 (5.6)

0

 No

39 (72.2)

35 (85.4)

 Yes

12 (22.2)

6 (14.6)

Permanent stoma

  

 Missing

3 (5.6)

0 (0)

 No

45 (79.6)

34 (82.9)

 Yes

8 (14.8)

7 (17.1)

Chemotherapy

  

 Missing

11 (20.4)

7 (17.1)

 No

37 (68.5)

27 (65.9)

 Yes

6 (11.1)

7 (17.1)

Radiotherapy

  

 Missing

10 (18.5 %)

7 (17.1)

 No

36 (66.7 %)

29 (70.7)

 Yes

8 (14.8 %)

5 (12.2)

Other treatment

  

 Missing

4 (7.4 %)

3 (7.3)

 No

49 (90.7 %)

35 (85.4)

 Yes

1 (1.9 %)

3 (7.3)

  1. aTNM stands for Tumour, Node, and Metastases. This staging system describes the size of a primary tumour (T), whether any lymph nodes contain cancer cells (N), and whether the cancer has spread to another part of the body (M)